This symposium session presented at the European Society for Medical Oncology (ESMO) 2022 included presentations exploring different and new aspects of treating patients with advanced cancers.
Development and Early Clinical Exploration of an MDM2-P53 Antagonist for Soft Tissue Sarcoma and Other Indications – 00:03:14
Speaker: Patrick Schöffski, MD, MPH
University Hospitals Leuven
Leuven, Belgium
Targeting HER2 and KRAS to Deliver Breakthrough Therapies – 00:36:02
Speaker: Egbert F. Smit, MD, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands
T-cell Engages: Changing the Treatment Paradigm in Solid Tumors – 00:59:48
Speaker: Martin Reck MD, PhD
Lung Clinic Grosshansdorf
Grosshansdorf, Germany
This content is funded by Boehringer Ingelheim International GmbH
